Felix Baker is the cofounder of Bakers Brothers Advisors, a New York-based hedge fund firm. The company specializes in biotechnology stocks.
According to Forbes, Baker is reported to have a net worth of $2.8 billion. He is the owner of the Oceanco yacht BARBARA.
| Name: | Felix Baker |
| Net Worth: | $2.8 Billion |
| Source of Wealth: | Bakers Brothers Advisors |
| Born: | 1971 |
| Country: | United States |
| Yacht: | BARBARA |
Felix Baker Net Worth
Baker has a net worth of $2.8 billion, thanks to his holdings in Bakers Brothers Advisors. Baker is the owner of the BARBARA superyacht.
BARBARA is a $150 million superyacht delivered from Oceanco in 2017. The impressive yacht was previously owned by Vladimir Potanin and named after his youngest daughter, Barbara.
Potanin is a Russian businessman and oligarch who decided to sell the yacht when he began building a larger vessel in the Netherlands. The yacht has a length of 88.5m.
Baker is also the owner of two private jets, a Bombardier Global 5000 and a Bombardier Global 6000.
Business
Felix Baker started a hedge fund firm with his brother Julian Baker in 2000. The Baker Brothers Advisors manages biotechnology stocks and contains $36 billion in stocks.
The fund manages long-term investments for major university endowments and foundations. Baker and his brother began their careers in fund management in 1994 with a biotechnology investing partnership with the Tisch Family.
The Tisch Family is one of the richest families in America, with a combined wealth of $6 billion.
Brothers Preston and Laurence Tisch built their wealth with investments. Their wives and sons now manage the fortune after the brothers’ deaths.
Personal Life
Baker was born in 1971. He is on the board of directors for three publicly traded companies, Seattle Genetics, Inc., Genomic Health, Inc., and Alexion Pharmaceuticals.
Alexion Pharmaceuticals develops and commercializes a range of therapeutic treatments.
Baker completed two years of medical school at Stanford University and also holds a B.S and a Ph. D in Immunology from Stanford. From 2000 to 2015, he served on the board of directors of Synageva BioPharma Corp.
